Published in AIDS Vaccine Week, October 31st, 2005
The patent number provided to IVT was 01 983 349.0-2402. All of the claims filed for the patent were allowed following modification of claims 43, 44 and 45, which were modified to conform to European patent presentation.
IVT is best known for its proprietary vaccine enhancement platform, VacciMax. The company has significantly advanced the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.